MP74-12 THROMBOEMBOLIC EVENTS AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH HEREDITARY THROMBOPHILIA DUE TO FACTOR V LEIDEN

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy IV (MP74)1 Apr 2020MP74-12 THROMBOEMBOLIC EVENTS AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH HEREDITARY THROMBOPHILIA DUE TO FACTOR V LEIDEN Sophie Knipper*, Jonas Ekrutt, Pierre Tennstedt, Hans Heinzer, Derya Tilki, and Markus Graefen Sophie Knipper*Sophie Knipper* More articles by this author , Jonas EkruttJonas Ekrutt More articles by this author , Pierre TennstedtPierre Tennstedt More articles by this author , Hans HeinzerHans Heinzer More articles by this author , Derya TilkiDerya Tilki More articles by this author , and Markus GraefenMarkus Graefen More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000960.012AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: With an incidence of about 5%, Factor V Leiden is the most common hereditary hypercoagulability among Caucasians. The increased risk of thromboembolic events is 5 to 8 fold in heterozygous and 10 to 25 fold in homozygous patients. In general, perioperative anticoagulation needs to be individualized, especially in oncological patients in whom pelvic surgery is planned. It is unknown if factor V Leiden patients may be at higher risk of thromboembolic events when treated with radical prostatectomy. METHODS: Within our prospectively collected database, we analyzed 30,871 prostate cancer patients treated with radical prostatectomy between 2001 and 2019. Of those, patients with factor V Leiden were identified. All patients received individualized recommendation of hemostaseologists for perioperative anticoagulation. Thromboembolic complications (deep vein thrombosis, pulmonary embolism) were assessed during hospital stay, as well as according to patient reported outcomes within the first three months after radical prostatectomy. RESULTS: Overall, 77 (0.3%) patients with known factor V Leiden were identified. Median age was 64 years (interquartile range: 61-68 years). Median follow-up was 37 months (IQR: 8-60 months). Within all 77 patients with factor V Leiden, none experienced thromboembolic complications within the first three months after surgery. CONCLUSIONS: In our cohort of patients with factor V Leiden, no thromboembolic events were observed after radical prostatectomy with individualized anticoagulation. This may reassure patients with this hereditary condition who are counselled for radical prostatectomy. Source of Funding: none © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1136-e1136 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sophie Knipper* More articles by this author Jonas Ekrutt More articles by this author Pierre Tennstedt More articles by this author Hans Heinzer More articles by this author Derya Tilki More articles by this author Markus Graefen More articles by this author Expand All Advertisement PDF downloadLoading ...